Literature DB >> 29120138

High Tumor Stroma Proportion is a Worse Prognostic Factor in Colorectal Cancer

Josipa Flam1,2, Damir Gugić1,2, Mirta Benšić3, Snježana Tomić4, Jasmina Rajc2,5.   

Abstract

High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer. Previous researches have shown that it might have a similar effect on colorectal cancer. The aim of this study was to determine whether tumor stroma proportion influenced patient survival. This retrospective study included 236 patients with colorectal cancer having undergone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the groups with high stroma proportion (>50%) and low stroma proportion (≤50%). Stroma proportion showed a statistically significant correlation with tumor stage. Kaplan-Meier survival curves yielded a statistically significant difference in patient overall survival (Cox ph model p=0.016) and progression-free survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statistically significantly shorter overall survival and progression-free survival in patients with high stroma proportion.

Entities:  

Keywords:  Colorectal neoplasms; Stromal cells; Survival; Disease-free survival; Disease progression; Prognosis

Mesh:

Year:  2017        PMID: 29120138     DOI: 10.20471/acc.2017.56.01.11

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


  2 in total

1.  Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.

Authors:  Emil Lou; Rachel I Vogel; Spencer Hoostal; Molly Klein; Michael A Linden; Deanna Teoh; Melissa A Geller
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 33.006

2.  Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Yuzhou Zhu; Zechuan Jin; Yuran Qian; Yu Shen; Ziqiang Wang
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.